<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35527277</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2047-9158</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>Translational neurodegeneration</Title>
          <ISOAbbreviation>Transl Neurodegener</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer's disease.</ArticleTitle>
        <Pagination>
          <StartPage>27</StartPage>
          <MedlinePgn>27</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">27</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s40035-022-00302-4</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Intracellular accumulation of the microtubule-associated protein tau and its hyperphosphorylated forms is a key neuropathological feature of Alzheimer's disease (AD). Melatonin has been shown to prevent tau hyperphosphorylation in cellular and animal models. However, the molecular mechanisms by which melatonin attenuates tau hyperphosphorylation and tau-related pathologies are not fully understood.</AbstractText>
          <AbstractText Label="METHODS">Immunofluorescence, immunoblotting analysis and thioflavin-S staining were employed to examine the effects of early and late treatment of melatonin on tau-related pathology in hTau mice, in which nonmutated human tau is overexpressed on a mouse tau knockout background. High-throughput microRNA (miRNA) sequencing, quantitative RT-PCR, luciferase reporter assay and immunoblotting analysis were performed to determine the molecular mechanism.</AbstractText>
          <AbstractText Label="RESULTS">We found that both early and late treatment of melatonin efficiently decreased the phosphorylation of soluble and insoluble tau at sites related to AD. Moreover, melatonin significantly reduced the number of neurofibrillary tangles (NFTs) and attenuated neuronal loss in the cortex and hippocampus. Furthermore, using miRNA microarray analysis, we found that miR-504-3p expression was upregulated by melatonin in the hTau mice. The administration of miR-504-3p mimics dramatically decreased tau phosphorylation by targeting p39, an activator of the well-known tau kinase cyclin-dependent kinase 5 (CDK5). Compared with miR-504-3p mimics alone, co-treatment with miR-504-3p mimics and p39 failed to reduce tau hyperphosphorylation.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Our results suggest for the first time that melatonin alleviates tau-related pathologies through upregulation of miR-504-3p expression by targeting the p39/CDK5 axis and provide novel insights into AD treatment strategies.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Chen</LastName>
            <ForeName>Dongmei</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Lan</LastName>
            <ForeName>Guihua</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Longyan First Hospital Affiliated to Fujian Medical University, Longyan, 364000, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Ruomeng</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mei</LastName>
            <ForeName>Yingxue</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shui</LastName>
            <ForeName>Xindong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Xi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Long</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gan</LastName>
            <ForeName>Chen-Ling</ForeName>
            <Initials>CL</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xia</LastName>
            <ForeName>Yongfang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Yuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Mi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Tae Ho</ForeName>
            <Initials>TH</Initials>
            <Identifier Source="ORCID">0000-0001-5968-1478</Identifier>
            <AffiliationInfo>
              <Affiliation>Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, Fujian, China. tlee0813@fjmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Transl Neurodegener</MedlineTA>
        <NlmUniqueID>101591861</NlmUniqueID>
        <ISSNLinking>2047-9158</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000620513">MIRN504 microRNA, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.22</RegistryNumber>
          <NameOfSubstance UI="C495906">Cdk5 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>JL5DK93RCL</RegistryNumber>
          <NameOfSubstance UI="D008550">Melatonin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051360" MajorTopicYN="Y">Cyclin-Dependent Kinase 5</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008550" MajorTopicYN="Y">Melatonin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Alzheimer’s disease</Keyword>
        <Keyword MajorTopicYN="Y">Melatonin</Keyword>
        <Keyword MajorTopicYN="Y">Tau</Keyword>
        <Keyword MajorTopicYN="Y">miR-504-3p</Keyword>
        <Keyword MajorTopicYN="Y">p39</Keyword>
      </KeywordList>
      <CoiStatement>The authors have declared that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>23</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35527277</ArticleId>
        <ArticleId IdType="pmc">PMC9082841</ArticleId>
        <ArticleId IdType="doi">10.1186/s40035-022-00302-4</ArticleId>
        <ArticleId IdType="pii">10.1186/s40035-022-00302-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263–269. doi: 10.1016/j.jalz.2011.03.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId>
            <ArticleId IdType="pmc">PMC3312024</ArticleId>
            <ArticleId IdType="pubmed">21514250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018;25(1):59–70. doi: 10.1111/ene.13439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.13439</ArticleId>
            <ArticleId IdType="pubmed">28872215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polanco JC, Li C, Bodea LG, Martinez-Marmol R, Meunier FA, Götz J. Amyloid-β and tau complexity—towards improved biomarkers and targeted therapies. Nat Rev Neurol. 2018;14(1):22–39. doi: 10.1038/nrneurol.2017.162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2017.162</ArticleId>
            <ArticleId IdType="pubmed">29242522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362–381. doi: 10.1097/NEN.0b013e31825018f7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId>
            <ArticleId IdType="pmc">PMC3560290</ArticleId>
            <ArticleId IdType="pubmed">22487856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8(9):663–672. doi: 10.1038/nrn2194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn2194</ArticleId>
            <ArticleId IdType="pubmed">17684513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 2009;32(3):150–159. doi: 10.1016/j.tins.2008.11.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tins.2008.11.007</ArticleId>
            <ArticleId IdType="pubmed">19162340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):5–21. doi: 10.1038/nrn.2015.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrn.2015.1</ArticleId>
            <ArticleId IdType="pubmed">26631930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tapia-Rojas C, Cabezas-Opazo F, Deaton CA, Vergara EH, Johnson GVW, Quintanilla RA. It's all about tau. Prog Neurobiol. 2019;175:54–76. doi: 10.1016/j.pneurobio.2018.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pneurobio.2018.12.005</ArticleId>
            <ArticleId IdType="pmc">PMC6397676</ArticleId>
            <ArticleId IdType="pubmed">30605723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med. 2009;15(3):112–119. doi: 10.1016/j.molmed.2009.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2009.01.003</ArticleId>
            <ArticleId IdType="pubmed">19246243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Watanabe A, et al. Hyperphosphorylation of tau in PHF. Neurobiol Aging. 1995;16(3):365–71; discussion 71–80.</Citation>
        </Reference>
        <Reference>
          <Citation>Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, et al.  Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res. 2005;2(1):3–18. doi: 10.2174/1567205052772713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1567205052772713</ArticleId>
            <ArticleId IdType="pubmed">15977985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris M, Maeda S, Vossel K, Mucke L. The many faces of tau. Neuron. 2011;70(3):410–426. doi: 10.1016/j.neuron.2011.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2011.04.009</ArticleId>
            <ArticleId IdType="pmc">PMC3319390</ArticleId>
            <ArticleId IdType="pubmed">21555069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimura T, Hosokawa T, Taoka M, Tsutsumi K, Ando K, Ishiguro K, et al.  Quantitative and combinatory determination of in situ phosphorylation of tau and its FTDP-17 mutants. Sci Rep. 2016;6:33479. doi: 10.1038/srep33479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep33479</ArticleId>
            <ArticleId IdType="pmc">PMC5027580</ArticleId>
            <ArticleId IdType="pubmed">27641626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi S, Saito T, Hisanaga S, Pant HC, Kulkarni AB. Tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for microtubules. The J Biol Chem. 2003;278(12):10506–10515. doi: 10.1074/jbc.M211964200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M211964200</ArticleId>
            <ArticleId IdType="pubmed">12536148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah K, Lahiri DK. Cdk5 activity in the brain—multiple paths of regulation. J Cell Sci. 2014;127(Pt 11):2391–2400. doi: 10.1242/jcs.147553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.147553</ArticleId>
            <ArticleId IdType="pmc">PMC4038939</ArticleId>
            <ArticleId IdType="pubmed">24879856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, et al.  Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 2003;38(4):555–565. doi: 10.1016/S0896-6273(03)00259-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0896-6273(03)00259-9</ArticleId>
            <ArticleId IdType="pubmed">12765608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell. 1997;89(2):297–308. doi: 10.1016/S0092-8674(00)80208-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(00)80208-1</ArticleId>
            <ArticleId IdType="pubmed">9108484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saito T, Oba T, Shimizu S, Asada A, Iijima KM, Ando K. Cdk5 increases MARK4 activity and augments pathological tau accumulation and toxicity through tau phosphorylation at Ser262. Hum Mol Genet. 2019;28(18):3062–3071. doi: 10.1093/hmg/ddz120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddz120</ArticleId>
            <ArticleId IdType="pubmed">31174206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin L, Huang QF, Yang S-S, Yang SF, Chu J, Chu JF, et al.  Melatonin in Alzheimer's disease. Int J Mol Sci. 2013;14(7):14575–14593. doi: 10.3390/ijms140714575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms140714575</ArticleId>
            <ArticleId IdType="pmc">PMC3742260</ArticleId>
            <ArticleId IdType="pubmed">23857055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, Zhang T, Lee TH. Cellular mechanisms of melatonin: insight from neurodegenerative diseases. Biomolecules. 2020;10(8):1158. doi: 10.3390/biom10081158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom10081158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ali T, Kim MO. Melatonin ameliorates amyloid beta-induced memory deficits, tau hyperphosphorylation and neurodegeneration via PI3/Akt/GSk3β pathway in the mouse hippocampus. J Pineal Res. 2015;59(1):47–59. doi: 10.1111/jpi.12238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jpi.12238</ArticleId>
            <ArticleId IdType="pubmed">25858697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardinali DP. Melatonin: clinical perspectives in neurodegeneration. Front Endocrinol (Lausanne) 2019;10:480. doi: 10.3389/fendo.2019.00480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2019.00480</ArticleId>
            <ArticleId IdType="pmc">PMC6646522</ArticleId>
            <ArticleId IdType="pubmed">31379746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song J. Pineal gland dysfunction in Alzheimer's disease: relationship with the immune-pineal axis, sleep disturbance, and neurogenesis. Mol Neurodegener. 2019;14(1):28. doi: 10.1186/s13024-019-0330-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13024-019-0330-8</ArticleId>
            <ArticleId IdType="pmc">PMC6624939</ArticleId>
            <ArticleId IdType="pubmed">31296240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gunata M, Parlakpinar H, Acet HA. Melatonin: A review of its potential functions and effects on neurological diseases. Rev Neurol (Paris) 2020;176(3):148–165. doi: 10.1016/j.neurol.2019.07.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurol.2019.07.025</ArticleId>
            <ArticleId IdType="pubmed">31718830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rudnitskaya EA, Maksimova KY, Muraleva NA, Logvinov SV, Yanshole LV, Kolosova NG, et al.  Beneficial effects of melatonin in a rat model of sporadic Alzheimer's disease. Biogerontology. 2015;16(3):303–316. doi: 10.1007/s10522-014-9547-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10522-014-9547-7</ArticleId>
            <ArticleId IdType="pubmed">25515660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dragicevic N, Copes N, O'Neal-Moffitt G, Jin J, Buzzeo R, Mamcarz M, et al.  Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. J Pineal Res. 2011;51(1):75–86. doi: 10.1111/j.1600-079X.2011.00864.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-079X.2011.00864.x</ArticleId>
            <ArticleId IdType="pubmed">21355879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res. 2003;35(2):125–130. doi: 10.1034/j.1600-079X.2003.00065.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1034/j.1600-079X.2003.00065.x</ArticleId>
            <ArticleId IdType="pubmed">12887656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res. 2005;38(3):145–152. doi: 10.1111/j.1600-079X.2004.00196.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-079X.2004.00196.x</ArticleId>
            <ArticleId IdType="pubmed">15725334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu YH, Feenstra MG, Zhou JN, Liu RY, Torano JS, Van Kan HJ, et al.  Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab. 2003;88(12):5898–5906. doi: 10.1210/jc.2003-030833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2003-030833</ArticleId>
            <ArticleId IdType="pubmed">14671188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, Mei Y, Kim N, Lan G, Gan CL, Fan F, et al.  Melatonin directly binds and inhibits death-associated protein kinase 1 function in Alzheimer's disease. J Pineal Res. 2020;69(2):e12665. doi: 10.1111/jpi.12665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jpi.12665</ArticleId>
            <ArticleId IdType="pmc">PMC7890046</ArticleId>
            <ArticleId IdType="pubmed">32358852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li SP, Deng YQ, Wang XC, Wang YP, Wang JZ. Melatonin protects SH-SY5Y neuroblastoma cells from calyculin A-induced neurofilament impairment and neurotoxicity. J Pineal Res. 2004;36(3):186–191. doi: 10.1111/j.1600-079X.2004.00116.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-079X.2004.00116.x</ArticleId>
            <ArticleId IdType="pubmed">15009509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi C, Zeng J, Li Z, Chen Q, Hang W, Xia L, et al.  Melatonin mitigates kainic acid-induced neuronal tau hyperphosphorylation and memory deficits through alleviating ER stress. Front Mol Neurosci. 2018;11:5. doi: 10.3389/fnmol.2018.00005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2018.00005</ArticleId>
            <ArticleId IdType="pmc">PMC5787934</ArticleId>
            <ArticleId IdType="pubmed">29416502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DL, Ling ZQ, Cao FY, Zhu LQ, Wang JZ. Melatonin attenuates isoproterenol-induced protein kinase A overactivation and tau hyperphosphorylation in rat brain. J Pineal Res. 2004;37(1):11–16. doi: 10.1111/j.1600-079X.2004.00130.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-079X.2004.00130.x</ArticleId>
            <ArticleId IdType="pubmed">15230863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luengo E, Buendia I, Fernández-Mendívil C, Trigo-Alonso P, Negredo P, Michalska P, et al.  Pharmacological doses of melatonin impede cognitive decline in tau-related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux. J Pineal Res. 2019;67(1):e12578. doi: 10.1111/jpi.12578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jpi.12578</ArticleId>
            <ArticleId IdType="pubmed">30943316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corpas R, Grinan-Ferre C, Palomera-Avalos V, Porquet D, Garcia de Frutos P, FranciscatoCozzolino SM, et al.  Melatonin induces mechanisms of brain resilience against neurodegeneration. J Pineal Res. 2018;65(4):e12515. doi: 10.1111/jpi.12515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jpi.12515</ArticleId>
            <ArticleId IdType="pubmed">29907977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Yang C, Wang J, Huang X, Yu H, Li S, et al.  Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer's disease. J Pineal Res. 2021;71:e12774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34617321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schonrock N, Ke YD, Humphreys D, Staufenbiel M, Ittner LM, Preiss T, et al.  Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta. PLoS ONE. 2010;5(6):e11070. doi: 10.1371/journal.pone.0011070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0011070</ArticleId>
            <ArticleId IdType="pmc">PMC2884018</ArticleId>
            <ArticleId IdType="pubmed">20552018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hebert SS, De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009;32(4):199–206. doi: 10.1016/j.tins.2008.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tins.2008.12.003</ArticleId>
            <ArticleId IdType="pubmed">19268374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Absalon S, Kochanek DM, Raghavan V, Krichevsky AM. MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J Neurosci. 2013;33(37):14645–14659. doi: 10.1523/JNEUROSCI.1327-13.2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1327-13.2013</ArticleId>
            <ArticleId IdType="pmc">PMC3810537</ArticleId>
            <ArticleId IdType="pubmed">24027266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Fatimy R, Li S, Chen Z, Mushannen T, Gongala S, Wei Z, et al.  MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways. Acta Neuropathol. 2018;136(4):537–555. doi: 10.1007/s00401-018-1880-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-018-1880-5</ArticleId>
            <ArticleId IdType="pmc">PMC6132948</ArticleId>
            <ArticleId IdType="pubmed">29982852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Tan L, Lu Y, Peng J, Zhu Y, Zhang Y, et al.  MicroRNA-138 promotes tau phosphorylation by targeting retinoic acid receptor alpha. FEBS Lett. 2015;589(6):726–729. doi: 10.1016/j.febslet.2015.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2015.02.001</ArticleId>
            <ArticleId IdType="pubmed">25680531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banzhaf-Strathmann J, Benito E, May S, Arzberger T, Tahirovic S, Kretzschmar H, et al.  MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease. EMBO J. 2014;33(15):1667–1680. doi: 10.15252/embj.201387576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.201387576</ArticleId>
            <ArticleId IdType="pmc">PMC4194100</ArticleId>
            <ArticleId IdType="pubmed">25001178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou TY, Zhou Y, Zhu LS, Wang X, Pang P, Wang DQ, et al.  Correcting abnormalities in miR-124/PTPN1 signaling rescues tau pathology in Alzheimer's disease. J Neurochem. 2020;154(4):441–457. doi: 10.1111/jnc.14961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.14961</ArticleId>
            <ArticleId IdType="pubmed">31951013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Chen W, Yi Y, Tong Q. miR-219-5p inhibits tau phosphorylation by targeting TTBK1 and GSK-3beta in Alzheimer's disease. J Cell Biochem. 2019;120(6):9936–9946. doi: 10.1002/jcb.28276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.28276</ArticleId>
            <ArticleId IdType="pubmed">30556160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis. 2019;40(3):422–431. doi: 10.1093/carcin/bgy186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgy186</ArticleId>
            <ArticleId IdType="pmc">PMC6514450</ArticleId>
            <ArticleId IdType="pubmed">30590435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Li X, Bi J, Chan MTV, Wu WKK, Shen J. Melatonin protected against the detrimental effects of microRNA-363 in a rat model of vitamin A-associated congenital spinal deformities: Involvement of Notch signaling. J Pineal Res. 2019;66(3):e12558. doi: 10.1111/jpi.12558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jpi.12558</ArticleId>
            <ArticleId IdType="pubmed">30653707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SJ, Kang HS, Lee JH, Park JH, Jung CH, Bae JH, et al.  Melatonin ameliorates ER stress-mediated hepatic steatosis through miR-23a in the liver. Biochem Biophys Res Commun. 2015;458(3):462–469. doi: 10.1016/j.bbrc.2015.01.117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2015.01.117</ArticleId>
            <ArticleId IdType="pubmed">25660457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Z, Qiu X, Gao B, Lian C, Peng Y, Liang A, et al.  Melatonin-mediated miR-526b-3p and miR-590-5p upregulation promotes chondrogenic differentiation of human mesenchymal stem cells. J Pineal Res. 2018;65(1):e12483. doi: 10.1111/jpi.12483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jpi.12483</ArticleId>
            <ArticleId IdType="pubmed">29498095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashrafizadeh M, Ahmadi Z, Yaribeygi H, Sathyapalan T, Jamialahmadi T, Sahebkar A. Antitumor and protective effects of melatonin: the potential roles of microRNAs. Adv Exp Med Biol. 2021;1328:463–471. doi: 10.1007/978-3-030-73234-9_31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-030-73234-9_31</ArticleId>
            <ArticleId IdType="pubmed">34981497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang K, Cai S, Xing Q, Qi Z, Fotopoulos V, Yu J, et al. Melatonin delays dark-induced leaf senescence by inducing miR171b expression in tomato. J Pineal Res. 2022.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Zhao R, Wu J, Wang Q, Pang K, Shi Q, et al.  Melatonin protects against Abeta-induced neurotoxicity in primary neurons via miR-132/PTEN/AKT/FOXO3a pathway. BioFactors. 2018;44(6):609–618. doi: 10.1002/biof.1411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/biof.1411</ArticleId>
            <ArticleId IdType="pubmed">29322615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang H, Ma M, Wu Y, Deng MF, Hu F, Almansoub H, et al.  Activation of MT2 receptor ameliorates dendritic abnormalities in Alzheimer's disease via C/EBPalpha/miR-125b pathway. Aging Cell. 2019;18(2):e12902. doi: 10.1111/acel.12902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/acel.12902</ArticleId>
            <ArticleId IdType="pmc">PMC6413662</ArticleId>
            <ArticleId IdType="pubmed">30706990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Wang ZH, Wu YY, Tang H, Tan L, Wang X, et al.  Melatonin attenuates scopolamine-induced memory/synaptic disorder by rescuing EPACs/miR-124/Egr1 pathway. Mol Neurobiol. 2013;47(1):373–381. doi: 10.1007/s12035-012-8355-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-012-8355-9</ArticleId>
            <ArticleId IdType="pubmed">23054680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim BM, You MH, Chen CH, Lee S, Hong Y, Hong Y, et al.  Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function. Cell Death Dis. 2014;5(5):e1237. doi: 10.1038/cddis.2014.216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2014.216</ArticleId>
            <ArticleId IdType="pmc">PMC4047864</ArticleId>
            <ArticleId IdType="pubmed">24853415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lazarevic V, Fienko S, Andres-Alonso M, Anni D, Ivanova D, Montenegro-Venegas C, et al.  Physiological concentrations of amyloid beta regulate recycling of synaptic vesicles via Alpha7 acetylcholine receptor and CDK5/calcineurin signaling. Front Mol Neurosci. 2017;10:221. doi: 10.3389/fnmol.2017.00221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2017.00221</ArticleId>
            <ArticleId IdType="pmc">PMC5520466</ArticleId>
            <ArticleId IdType="pubmed">28785201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das R, Balmik AA, Chinnathambi S. Melatonin reduces GSK3β-mediated tau phosphorylation, enhances Nrf2 nuclear translocation and anti-inflammation. ASN Neuro. 2020;12:1759091420981204. doi: 10.1177/1759091420981204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1759091420981204</ArticleId>
            <ArticleId IdType="pmc">PMC7754800</ArticleId>
            <ArticleId IdType="pubmed">33342257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, et al.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86(3):582–590. doi: 10.1046/j.1471-4159.2003.01879.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1471-4159.2003.01879.x</ArticleId>
            <ArticleId IdType="pubmed">12859672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009;29(34):10741–10749. doi: 10.1523/JNEUROSCI.1065-09.2009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1065-09.2009</ArticleId>
            <ArticleId IdType="pmc">PMC2760256</ArticleId>
            <ArticleId IdType="pubmed">19710325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frost B, Hemberg M, Lewis J, Feany MB. Tau promotes neurodegeneration through global chromatin relaxation. Nat Neurosci. 2014;17(3):357–366. doi: 10.1038/nn.3639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn.3639</ArticleId>
            <ArticleId IdType="pmc">PMC4012297</ArticleId>
            <ArticleId IdType="pubmed">24464041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun W, Samimi H, Gamez M. Pathogenic tau-induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies. Nat Neurosci. 2018;21(8):1038–1048. doi: 10.1038/s41593-018-0194-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41593-018-0194-1</ArticleId>
            <ArticleId IdType="pmc">PMC6095477</ArticleId>
            <ArticleId IdType="pubmed">30038280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang D, Yeung J, Lee KY, Matsushita M, Matsui H, Tomizawa K, et al.  An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J Biol Chem. 1995;270(45):26897–26903. doi: 10.1074/jbc.270.45.26897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.270.45.26897</ArticleId>
            <ArticleId IdType="pubmed">7592934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, et al.  APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol. 2003;163(1):83–95. doi: 10.1083/jcb.200301115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.200301115</ArticleId>
            <ArticleId IdType="pmc">PMC2173445</ArticleId>
            <ArticleId IdType="pubmed">14557249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee VM, Balin BJ, Otvos L, Jr, Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science. 1991;251(4994):675–678. doi: 10.1126/science.1899488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1899488</ArticleId>
            <ArticleId IdType="pubmed">1899488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8(1):159–168. doi: 10.1016/0896-6273(92)90117-V.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0896-6273(92)90117-V</ArticleId>
            <ArticleId IdType="pubmed">1530909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O'Connor M, Trojanowski JQ, et al.  Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron. 1994;13(4):989–1002. doi: 10.1016/0896-6273(94)90264-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0896-6273(94)90264-X</ArticleId>
            <ArticleId IdType="pubmed">7946342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balmik AA, Das R, Dangi A, Gorantla NV, Marelli UK, Chinnathambi S. Melatonin interacts with repeat domain of Tau to mediate disaggregation of paired helical filaments. Biochim Biophys Acta Gen Subj. 2020;1864(3):129467. doi: 10.1016/j.bbagen.2019.129467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagen.2019.129467</ArticleId>
            <ArticleId IdType="pubmed">31715192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25(22):5446–5454. doi: 10.1523/JNEUROSCI.4637-04.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.4637-04.2005</ArticleId>
            <ArticleId IdType="pmc">PMC6725006</ArticleId>
            <ArticleId IdType="pubmed">15930395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Improta-Caria AC, Nonaka CKV, Cavalcante BRR, De Sousa RAL, Aras Júnior R, Souza BSF. Modulation of microRNAs as a potential molecular mechanism involved in the beneficial actions of physical exercise in Alzheimer disease. Int J Mol Sci. 2020;21(14):4977. doi: 10.3390/ijms21144977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21144977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu SL, Wang C, Jiang T, Tan L, Xing A, Yu JT. The role of Cdk5 in Alzheimer's disease. Mol Neurobiol. 2016;53(7):4328–4342. doi: 10.1007/s12035-015-9369-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-015-9369-x</ArticleId>
            <ArticleId IdType="pubmed">26227906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turab Naqvi AA, Hasan GM, Hassan MI. Targeting Tau hyperphosphorylation via kinase inhibition: strategy to address Alzheimer's disease. Curr Top Med Chem. 2020;20(12):1059–1073. doi: 10.2174/1568026620666200106125910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1568026620666200106125910</ArticleId>
            <ArticleId IdType="pubmed">31903881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castro-Alvarez JF, Uribe-Arias SA, Kosik KS, Cardona-Gómez GP. Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer's mice. Front Aging Neurosci. 2014;6:243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4159979</ArticleId>
            <ArticleId IdType="pubmed">25309427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piedrahita D, Hernández I, López-Tobón A, Fedorov D, Obara B, Manjunath BS, et al.  Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice. J Neurosci. 2010;30(42):13966–13976. doi: 10.1523/JNEUROSCI.3637-10.2010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.3637-10.2010</ArticleId>
            <ArticleId IdType="pmc">PMC3003593</ArticleId>
            <ArticleId IdType="pubmed">20962218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai LH, Delalle I, Caviness VS, Jr, Chae T, Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature. 1994;371(6496):419–423. doi: 10.1038/371419a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/371419a0</ArticleId>
            <ArticleId IdType="pubmed">8090221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402(6762):615–622. doi: 10.1038/45159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/45159</ArticleId>
            <ArticleId IdType="pubmed">10604467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patzke H, Tsai LH. Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29. J Biol Chem. 2002;277(10):8054–8060. doi: 10.1074/jbc.M109645200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109645200</ArticleId>
            <ArticleId IdType="pubmed">11784720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvira D, Tajes M, Verdaguer E, Acuña-Castroviejo D, Folch J, Camins A, et al.  Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J Pineal Res. 2006;40(3):251–258. doi: 10.1111/j.1600-079X.2005.00308.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-079X.2005.00308.x</ArticleId>
            <ArticleId IdType="pubmed">16499562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardinali DP, Vigo DE, Olivar N, Vidal MF, Brusco LI. Melatonin therapy in patients with Alzheimer's disease. Antioxidants (Basel) 2014;3(2):245–277. doi: 10.3390/antiox3020245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/antiox3020245</ArticleId>
            <ArticleId IdType="pmc">PMC4665493</ArticleId>
            <ArticleId IdType="pubmed">26784870</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
